SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-013717
Filing Date
2020-11-12
Accepted
2020-11-12 16:29:47
Documents
69
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20200930x10q.htm 10-Q 1700020
2 EX-31.1 akro-20200930ex311abe3d8.htm EX-31.1 10364
3 EX-31.2 akro-20200930ex312421199.htm EX-31.2 11272
4 EX-32.1 akro-20200930ex3211d47e6.htm EX-32.1 10485
  Complete submission text file 0001558370-20-013717.txt   6551208

Data Files

Seq Description Document Type Size
5 EX-101.INS akro-20200930.xml EX-101.INS 1419832
6 EX-101.SCH akro-20200930.xsd EX-101.SCH 46532
7 EX-101.CAL akro-20200930_cal.xml EX-101.CAL 35880
8 EX-101.DEF akro-20200930_def.xml EX-101.DEF 123840
9 EX-101.LAB akro-20200930_lab.xml EX-101.LAB 436755
10 EX-101.PRE akro-20200930_pre.xml EX-101.PRE 315777
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 201307183
SIC: 2834 Pharmaceutical Preparations